Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Retained Earnings (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Retained Earnings for 15 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.01% to $50000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2025, up 100.01% year-over-year, with the annual reading at $50000.0 for FY2025, 100.01% up from the prior year.
  • Retained Earnings hit $50000.0 in Q4 2025 for Cardiff Oncology, up from -$422.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $50000.0 in Q4 2025 to a low of -$422.8 million in Q3 2025.
  • Historically, Retained Earnings has averaged -$205.3 million across 5 years, with a median of -$276.0 million in 2022.
  • Biggest five-year swings in Retained Earnings: plummeted 2812480.0% in 2022 and later surged 120.45% in 2025.
  • Year by year, Retained Earnings stood at -$142000.0 in 2021, then plummeted by 209829.58% to -$298.1 million in 2022, then dropped by 13.9% to -$339.5 million in 2023, then decreased by 13.15% to -$384.2 million in 2024, then skyrocketed by 100.01% to $50000.0 in 2025.
  • Business Quant data shows Retained Earnings for CRDF at $50000.0 in Q4 2025, -$422.8 million in Q3 2025, and $17000.0 in Q2 2025.